Share This Article:

Immunological Variations in Epileptic Children

Abstract Full-Text HTML XML Download Download as PDF (Size:349KB) PP. 71-91
DOI: 10.4236/ojapps.2013.31012    3,836 Downloads   6,172 Views   Citations


Epilepsy is one of the most frequent neurological problems. Despite of the advances and improvements in treatment of seizure disorders, immunological alterations such as immunoglobulins and complements have been measured. The levels of IgG in epileptic patients are found to be higher than controls. The levels of IgA, IgM, C3 and C4 were found to be lower in all the controls. Student’s t-test were also applied. Multiple and regression analysis, have been also carried out. A trend has also set up in the present study. An alteration in the immune mechanism of epileptic patients is required. Ketogenic diet may be given and the balance of trace elements like Na, K, Zn, Fe, Ca, Mg and Cu may be maintained to alter the immune mechanism of the epileptic patients. Green leafy vegetables may be given to the patients to control the seizure. Immunity is related with the food we eat. By adjusting the immunity with proper diet the severity of epileptic attack or any disease may be reduced.

Conflicts of Interest

The authors declare no conflicts of interest.

Cite this paper

S. Kumar, V. Kumar, D. Jain and R. Mittal, "Immunological Variations in Epileptic Children," Open Journal of Applied Sciences, Vol. 3 No. 1, 2013, pp. 71-91. doi: 10.4236/ojapps.2013.31012.


[1] P. Ehrlich, “Das Sauerstufbudurfnis des Organismus, in Eine Farbenanalytische Studie,” Hirschwald, Berlin, 1885, p. 167.
[2] J. B. Murphy and E. Sturm, “Conditions Determining the Transplantability of Tissues in the Brain,” The Journal of Experimental Medicine, Vol. 39, No. 2, 1923, pp. 183-197. doi:10.1084/jem.38.2.183
[3] F. R. Sabin, “The Origin and Development of the Lymphatic System,” Johns Hopkins Hospital Research, Vol. 17, No. 86, 1916, pp. 347-440.
[4] M. Ediden, “The Tissue Distribution and Cellular Location of Transplantation Antigens,” In: B. D. Kanhan and R. A. Reisfeld, Eds., Transplantation Antigens, Academic Press Inc., New York, 1972, pp. 125-140.
[5] J. E. Blalock, “The Immune System as a Sensory Organ,” The Journal of Immunology, Vol. 132, No. 3, 1984, pp. 1067-1070.
[6] S. Reichlin, “Neuroendocrine-Immune Interactions,” The New England Journal of Medicine, Vol. 329, No. 17, 1993, pp. 1246-1253. doi:10.1056/NEJM199310213291708
[7] E. M. Sternberg, G. P. Chrousos, R. L. Wilder and P. W. Gold, “The Stress Response and the Regulation of Inflam matory Disease,” Annals of Internal Medicine, Vol. 117, No. 10, 1992, pp. 854-866.
[8] D. A. Weigent and J. E. Blalock, “Interactions between the Neuroendocrine and Immune Systems: Common Hormones Receptors,” Immunological Reviews, Vol. 100, 1987, pp. 79-108. doi:10.1111/j.1600-065X.1987.tb00528.x
[9] W. W. Tourtellotte, “On Cerebrospinal Fluid Immunoglo bulinG (IgG) Quotients in Multiple Sclerosis and Other Diseases. A Review and a New Formula to Estimate the Amount of IgG Synthesized Per Day by the Central Nervous System,” Journal of the Neurological Sciences, Vol. 10, No. 3, 1970, pp. 279-304.
[10] M. B. Oldstone and F. J. Dixon, “Immunohistochemical Study of Allergic Encephalomyelitis,” American Journal of Pathology, Vol. 52, No. 2, 1968, pp. 251-263.
[11] S. D. Miller, C. L. Vanderlugt, W. S. Begolka, W. Pao, R. L. Yauch, K. L. Neville, Y. Katz-Levy, A. Carrizosa and B. S. Kim, “Persistent Infection with Theiler’s Virus Leads to CNS Autoimmunity via Epitope Spreading,” Nature Medicine, Vol. 3, No. 10, 1997, pp. 1133-1136. doi:10.1038/nm1097-1133
[12] V. Agnello, “Complement Deficiency States,” Medicine, Vol. 57, No. 1, 1987, pp. 1-23.
[13] D. T. Fearon, “Structure and Functions of Compliment,” In: M. Z. Ataasi, C. J. Vanoss and D. R. Absolon, Eds., Molecular Immunology, Marcel Dekker, Inc., New York, 1987, p. 511.
[14] J. E. Valanakis, “The Human Complement System,” Journal of Oral Pathology, Vol. 4, No. 4, 1975, pp. 195 221. doi:10.1111/j.1600-0714.1975.tb01742.x
[15] J. H. Stein, “Complement Measurement,” In: S. Puddy, Ed., Internal Medicine, 2nd Edition, Little Brown and Company, Boston, Toranto, 1987, p. 1184.
[16] R. A. Fishman, “Cerebrospinal Fluid in Disorders of the Nervous System,” W.B. Sounders, Philadelphaia, London, Toranto, 1980, pp. 95-107.
[17] T. C. Milica, V. Brinar, M. Pauro, ?. Vogrine and N. Stambuk, “Cerebrospinal Fluid Complement Activation in Neurological Diseases,” Journal of the Neurological Sciences, Vol. 154, No. 2, 1998, pp. 173-181. doi:10.1016/S0022-510X(97)00225-6
[18] P. T. Golwmbek, “Immunomodulation of Epilepsy,” In: J. M. Rho, R. Sankar and J. E. Cavazos., Eds., Epilepsy, Scientific Foundations of Clinical Practice, Marcel Dekker, Inc., New York, 2004, pp. 299-317.
[19] P. A. Bouma, “Determining the Prognosis of Child Hood Epilepsies by Establishing Immune Abnormalities,” Clinical Neurology and Neurosurgery, Vol. 94, No. S, 1992, pp. 54-56.
[20] Y. P. Gholamali, S. Izadi and A. Ghaderi, “Immunologi cal Correlates of Adult Onset Idiopathic Generalized Tonic-Clonic Epilepsy before and after Sodiuurm Val proate Treatment,” Iranian Journal of Immunology, Vol. 1, No. 2, 2004, pp. 105-110.
[21] G. M. V. E. Baziel, W. O. Renier, C. M. Weemaes, F. J. Gabreels and H. Meinardi, “Immunoglobulin Treatment in Epilepsy. A Review of the Literature,” Epilepsy Research, Vol. 19, No. 3, 1994, pp. 181-190. doi:10.1016/0920-1211(94)90061-2
[22] J. Savory and M. G. Heintges, “Cerebrospinal Fluid Levels of IgG, IgA and IgM in Neurological Diseases,” Neurology, Vol. 23, No. 9, 1973, pp. 953-958. doi:10.1212/WNL.23.9.953
[23] M. Masi, P. Paolucci, P. Perocco and C. Franceschi, “Im munosupression by Phenytion,” The Lancet, Vol. 307, No. 7964, 1976, pp. 860-860. doi:10.1016/S0140-6736(76)90511-0
[24] M. Bassanini, A. Baez and J. Sotelo, “Immunoglobulins in Epilepsy,” Journal of the Neurological Sciences, Vol. 56, No. 2-3, 1982, pp. 275-281. doi:10.1016/0022-510X(82)90148-4
[25] E. A. Walker, “Allergic Phenomena as Basicmechanisms of the Epilepsies,” In: H. H. Jansper, A. A. Ward Jr. and A. Pope, Eds., Basic Mechanisms of Epilepsies, Churchill, London, Boston, 1969, p. 812.
[26] G. Ettlinger and M. B. Lowrie, “An Immunological Factor in Epilepsy,” Lancet, Vol. 307, No. 7974, 1976, p. 1386. doi:10.1016/S0140-6736(76)93031-2
[27] A. Amman and R. Hong, “Selective IgG Deficiency,” In: E. R. Stiehm and V. A., Fulginiti Eds., Immunological Disorders in Infants and Children, W.B. Saunders, Co., Philadelphia, 1973, pp. 199-214.
[28] B. N. Slavin, G. M. Fenton, M. Laundry and E. H. Reynolds, “Serum Immunoglobulin in Epilepsy,” Journal of the Neurological Sciences, Vol. 23, No. 3, 1974, pp. 353-357. doi:10.1016/0022-510X(74)90153-1
[29] J. Seager, J. Wilson, D. L. Jamison, A. R. Hayward and J. F. Soothill, “IgA Deficeiency, Epilepsy, and Phenytoin Treatment,” Lancet, Vol. 306, No. 7936, 1975, pp. 632-635. doi:10.1016/S0140-6736(75)90115-4
[30] P. J. Grob and G. E. Herold, “Immunological Abnormali ties and Hydantoins,” British Medical Journal, Vol. 2, No. 5813, 1972, pp. 561-563. doi:10.1136/bmj.2.5813.561
[31] A. J. Amman and R. Hong, “Selective IgA Deficiency: Presentation of 30 Cases and a Review of the Literature,” Medicine, Vol. 50, No. 3, 1971, pp. 223-236. doi:10.1097/00005792-197105000-00004
[32] S. Yabuki and K. Nakaya, “Immunoglobulin Abnormali ties in Epileptic Patients Treated with Diphenylhydantion,” Folia Psychiatrica et Neurologica Japonica, Vol. 30, No. 2, 1976, pp. 93-109.
[33] M. Allansmith, B. Wymer and G. Prieto, “Repeated Immunoglobulin Determinations in 15 Individuals over a Six Month Period,” Journal of Allergy, Vol. 37, No. 2, 1966, p. 114.
[34] P. Anderson and L. Moseklide, “Immunoglobulin Levels and Autoantibodies in Epileptics on Long-Term Anticonvulsant Therapy,” Acta Medica Scandinavica, Vol. 201, No. 1-2, 1977, pp. 69-74.
[35] H. Matsuoka, J. Okada, T. Takashashi, M. Matsuoka, C. Sato and S. Toorii, “Immunological Study of IgA Defi ciency during Anticonvulsant Therapy in Epileptic Patients,” Clinical & Experimental Immunology, Vol. 53, No. 2, 1983, pp. 423-428.
[36] R. A. Shakir, P. O. Behan, H. Dick and D. G. Lambie, “Metabolism of Immunoglobulin A, Lymphocyte Function, and Histocompatibility Antigens in Patients on Anticonvulsants,” Journal of Neurology, Neurosurgery & Psychiatry, Vol. 41, No. 4, 1978, pp. 307-311. doi:10.1136/jnnp.41.4.307
[37] U. K. Dashora, A. Pangariya and B. M. Sharma, “Immunoglobulin abnormalities in epileptics,” Journal of Indian Medical Association, Vol. 84, No. 2, 1986, pp. 66-67.
[38] J. A. Aarli and A. Fontana, “Immunological Aspects of Epilepsy,” Epilepsia, Vol. 21, No. 5, 1980, pp. 451-457. doi:10.1111/j.1528-1157.1980.tb04295.x
[39] J. A. Aarli, “Immunological Aspects of Epilepsy,” Brain & Development, Vol. 15, No. 1, 1993, pp. 41-49. doi:10.1016/0387-7604(93)90005-S
[40] H. K. Al-Hakeim, “Serm Cortisol Immunoglobulins and Some Complements among Depressed Patients,” Indian Journal of Clinical Biochemistry, Vol. 23, No. 1, 2008, pp. 76-80. doi:10.1007/s12291-008-0018-2
[41] B. R. Mirdha, “Status of Toxoplasma Gondii in the Etiology of Epilepsy,” Journal of Pediatric Neurology, Vol. 1, No. 2, 2003, pp. 95-98.
[42] D. Riddoch and R. A. Thompson, “Immunoglobulin Levels in the Cerebrospinal Fluid,” British Medical Journal, Vol. 1, No. 5693, 1970, pp. 396-399. doi:10.1136/bmj.1.5693.396
[43] P. Mc. Callenbach, C. M. J.-V. Der Zijde, A. T. Geerts, W. F. Arts, C. A. Van Donselaar, A. C. Peters, H. Stroink, O. F. Brouwer and M. J. Van Tol, “Immunoglobulins in Children with Epilepsy: The Dutch Study of Epilepsy in Childhood,” Clinical & Experimental Immunology, Vol. 132, No. 1, 2003, pp. 144-151.
[44] M. Ashrafi, S. A. Hosseini, S. Abolmaali, M. Biglari, R. Aziz, M. Farghadan, A. Samadian, S. Saghafi, H. Mom beini, N. Saladjegheh, N. Rezaei and A. AghaMohammed, “Effect of Anti-Epiteptic Drugs on Serum Immunoglobu lin Levels in Children,” Acta Neurologica Belgica, Vol. 110, No. 1, 2010, pp. 65-70.
[45] S. Bostantjopoulou, O. Hatzizisi, O. Argyropoulou, S. Andreadis, K. Deligiannis, M. Kantaropoulou, A. Kazis, G. Kyrazis and K. Routsonis, “Immunological Parameters in Patients with Epilepsy,” Functional Neurology, Vol. 9, No. 1, 1994, pp. 11-15.
[46] F. De Ponti, S. Lecchini, M. Cosentino, C. M. Castelletti, A. Malesci and G. M. Frigo, “Immunological Adverse Effects of Anticonvulsant, What Is Their Clinical Rele vance?” Drug Safety, Vol. 8, No. 3, 1993, pp. 235-250. doi:10.2165/00002018-199308030-00005
[47] A. Basta-Kaim, B. Budziszewska and W. Lason, “Effects of Anti Epileptic Drugs on Immune System,” Przeglad Lekarski, Vol. 65, No. 11, 2008, pp. 799-802.
[48] J. Ranua, K. Luoma, A. Auvinen, J. Peltola, A. M. Haapala, J. Raitanen and J. Isojarvi, “Serum IgA, IgG, and IgM, Concentrations in Patients with Epilepsy and Matched Controls: A Cohort-Based Cross Sectional Study,” Epilepsy & Behavior, Vol. 6, No. 2, 2005, pp. 191-195. doi:10.1016/j.yebeh.2004.11.017
[49] E. J. Bardana Jr., J. D. Gabourel, G. H. Davies and S. Craig, “Effects of Phenytoin on Man’s Immunity. Evaluation of Changes in Serum Immunoglobulins, Complement, and Antinuclear Antibody,” American Journal of Medicine, Vol. 74, No. 2, 1983, pp. 289-296.
[50] A. Vezzani, “Innate Immunity and Inflammation in Tem poral Lobe Epilepsy: New Emphasis on the Role of Complement Activation,” Epilepsy Currents, Vol. 8, No. 3, 2008, pp. 75-77. doi:10.1111/j.1535-7511.2008.00243.x
[51] E. Aronica, K. Boer, E. A. Van Vliet, S. Redeker, J. C. Baayen, W. G. M. Spliet, P. C. Van Rijen, D. Troost, F. H. Lopes da Silva, W. J. Wadman and J. A. Goter, “Complement Activation in Experimental and Human Temporal Lobe Epilepsy,” Neurobiology of Disease, Vol. 26, No. 3, 2007, pp. 497-511. doi:10.1016/j.nbd.2007.01.015
[52] P. Price and M. L. Cuzner, “Cerebrospinal Fluids Complement Proteins in Neurological Disease,” Journal of the Neurological Sciences, Vol. 46, No. 1, 1980, pp. 49-54. doi:10.1016/0022-510X(80)90042-8
[53] N. Basaran, F. Hincal, E. Kansu and A. Ciger, “Humoral and Cellular Immune Parameters in Untreated and Phenytoin or Carbamazepine Treated Epileptic Patients,” International Journal of Immunopathology and Pharmacology, Vol. 16, No. 12, 1994, pp. 1071-1077.
[54] B. Oettinger and K. Richter, “Antiepileptic Drug Levels and Side Effects in Man,” Monoger Neurological Science, Vol. 5, 1980, pp. 240-244.
[55] N. E. Gilhus and J. A. Aarli, “Respiratory Disease and Nasal Immunoglobulin Concentrations in Phenytion treated Epileptic Patients,” Acta Neurologica Scandina vica, Vol. 63, No. 1, 1981, pp. 34-43. doi:10.1111/j.1600-0404.1981.tb00746.x
[56] G. Mancini, A. O. Carbonara and J. F. Heremans, “Immu nochemical Quantitation of Antigens by Single Radical Immunodiffusion,” Immunochemistry, Vol. 2, No. 3, 1965, pp. 235-254.
[57] R. Olsson, “Plasma Proteins in Patients on Long Term Anti Epilepthic Treatment,” Clinical Chemistry, Vol. 29, No. 4, 1983, pp. 728-730.
[58] S. Moustafa, A. Osama, A. Saad, S. El-Seed and N. Moustafa, “Immunotoxicity of Chronic Phenytoin Administration in Epileptic Patients,” Egyptian Journal of Neurology, Psychiatry and Neurosurgery, Vol. 43, No. 1, 2006, pp. 435-441.
[59] S. Kumar, “Medico-Physical Studies on Epilepsy and Other Neurological Disorders,” Ph.D Thesis, University of Delhi, Delhi, 1989.
[60] T. L. Moore, R. E. Ryan Jr., D. A. Pohl and S. T. Roodman and R. E. Sr. Ryan, “Immunoglobulin, Complement, and Immune Complex Levels during a Migrane Attack,” Headache: The Journal of Headache and Face Pain, Vol. 20, No. 1, 1980, pp. 9-12.
[61] G. D. A. Lord and J. W. Duchworth, “Immunoglobulin and Complement Studies in Migrane,” Headache: The Journal of Head and Face Pain, Vol. 17, No. 4, 1977, pp. 163-168. doi:10.1111/j.1526-4610.1977.hed1704163.x
[62] T. Granata, H. Cross, W. Theodore and G. Avanzini, “Im mune-Mediated Epilepsies,” Epilepsia, Vol. 52, No. Suppl 3, 2001, pp. 5-11.

comments powered by Disqus

Copyright © 2018 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.